Prescription Medicines
Headache Cap.
- Product Category
- Migraine, sage treatment
- Active Ingredients
- Flunarizine hydrochloride
- Appearance
- Hard capsule containing white powder, dark gray at the top and light red at the bottom.
- Reimbursement Code
- 648102410
01 / 03
1. Composition and Strength
Of 1 capsule
- Active ingredient: : Flunarizine hydrochloride (KP)----5.9mg (5mg as flunarizine)
- Additives (tar coloring): Red No. 3
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, capsule, colloidal silicon dioxide, talc
2. Effectiveness
1. Severe, intractable migraine
2. Dizziness due to dysfunction of the vestibular system
3. Dosage and dosage
1. Severe, intractable migraine
Initial dose: Flunarizine, 10 mg once, is administered orally in the evening once a day for adults under 65 years of age (5 mg once a time for adults over 65 years of age). If depression, extrapyramidal symptoms, or other severe side effects occur, or if symptoms do not improve after two months of administration, discontinue administration.
Maintenance dose: If maintenance therapy is necessary, administer 10 mg of this drug once every 2 days (5 mg once for those over 65 years of age) or reduce the dosage by administering 10 mg once a day for 5 days a week (5 mg once for those over 65 years of age) (take a break for 2 days). In addition, as maintenance therapy to prevent migraine, even if migraine symptoms do not appear, administration should be discontinued 6 months after the first dose, and only if symptoms recur, the dose should be restarted from the initial dose.
2. Dizziness due to dysfunction of the vestibular system: The Dosage and Administration are the same as for migraine, but the initial dose should not last longer than the period necessary to control dizziness symptoms (generally 2 months). In addition, if there is no clear improvement in symptoms even after taking the drug for 1 month for chronic dizziness or 2 months for paroxysmal dizziness, stop taking the drug.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients who did not completely stop bleeding after intracranial hemorrhage
2) Patients with acute myocardial infarction
3) Parkinson's disease patients
4) Patients with depressive symptoms or a history of depression
5) Pregnant women or women who may be pregnant
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients:
1) Patients with liver impairment
2) Elderly people
3. Adverse reactions
1) Clinical trial data
① Placebo control group, double-blind trial - Adverse drug reactions reported at a frequency of more than 1%
The safety of this drug (5 to 10 mg/day) was evaluated in 500 subjects (247 in the treatment group and 253 in the placebo group) who participated in two placebo-controlled, double-blind parallel clinical trials (one for the treatment of migraine and one for the treatment of dizziness).
Adverse drug reactions reported in more than 1% of patients receiving this drug are shown in Table 1 below.
Table 1. Adverse drug reactions reported in more than 1% of patients treated with this drug in two placebo-controlled, double-blind parallel clinical trials
※ Please check the attached document for details.
② Active control test - Adverse drug reactions reported at a frequency of more than 1%
To determine the incidence of adverse drug reactions, two double-blind, active control trials were conducted. In these two trials, 476 subjects received 10 mg/day of this drug, one for migraine and the other for the treatment of dizziness or migraine.
Table 2 below lists adverse drug reactions reported in at least 1% of patients receiving this medicine in active-controlled studies that are not included in Table 1.
Table 2. Adverse drug reactions reported in more than 1% of patients treated with this drug in two double-blind active-controlled trials
※ Please check the attached document for details.
③ Placebo and active control trials - Adverse drug reactions reported with an incidence of less than 1%
Among the two clinical trial data above, Table 3 shows additional adverse drug reactions that occurred in less than 1% of patients administered this drug.
Table 3. Adverse drug reactions reported in less than 1% of patients treated with this drug in placebo and active control trials
※ Please check the attached document for details.
2) Post-marketing data
Table 4 shows the adverse drug reactions first discovered in post-marketing experience with this drug. In the table, the frequencies are indicated as follows.
Very common ≥ 1/10
Common: ≥1/100 and <1/10
Uncommon: ≥1/1,000 and <1/100
Rarely ≥ 1/10,000 and < 1/1,000
Very rare <1/10,000, with isolated reports
Table 4. Adverse drug reactions identified in post-marketing experience with this drug according to frequency estimated from voluntary reporting rates
※ Please check the attached document for details.
3) Mental nervous system: Depressive symptoms may occur, so pay close attention to the patient's condition and discontinue administration if such symptoms appear.
4) Extrapyramidal symptoms: Extrapyramidal symptoms such as convulsions, decreased motor function, mask-like face, forward flexion posture, lip dyskinesia, tremor, stiffness, and gait disturbance may occur. In such cases, discontinue administration. In severe cases, take appropriate measures, such as administering anti-Parkinson drugs.
5) Liver: Rarely, elevations of AST, ALT, ALP, and LDH may occur, so observe thoroughly and discontinue administration if abnormalities are recognized.
6) Hypersensitivity: In rare cases, a rash may occur, so pay close attention to the patient's condition and discontinue administration if such symptoms appear.
7) Digestive system: In rare cases, dry mouth, stomach discomfort, constipation, nausea, loss of appetite, and diarrhea may occur.
8) Others: Occasionally, drowsiness, fatigue, helplessness, malaise, headache, dizziness, staggering, insomnia, facial flushing, weight gain, edema, urinary retention, excessive milk secretion, etc. may occur (excessive milk secretion is more common in women taking oral contraceptives).
4. General precautions
1) While taking this medicine, you may experience decreased motor function, a mask-like face, extrapyramidal symptoms or depressive symptoms, mainly in the anteversion posture (there are also reports that it is more common in women).
Since these symptoms may appear for several months after discontinuation of administration, pay attention to the following.
① While administering this drug, carefully observe the patient's condition and pay attention to early detection of extrapyramidal symptoms and depression symptoms. If these symptoms are suspected or appear, the administration should be discontinued immediately.
② In cases where extrapyramidal symptoms appear, observe thoroughly as activities of daily living, such as going up and down stairs or putting on and taking off clothes, may worsen.
③ Efficacy should be assessed approximately 2 months after starting this drug, and administration thereafter is as follows.
․If the effect is recognized: Check the effect regularly (about 1 month) and decide whether to administer it.
․If the effect is not recognized: Stop.
․If the effect cannot be judged: Take a temporary break from the medication and decide whether to administer it after sufficiently observing the condition of the patient.
2) Because it may cause drowsiness and lethargy, patients taking this medicine should be careful not to operate dangerous machinery, such as driving a car.
5. Interaction
1) When coadministered with antihypertensive agents, it is advisable to adjust the dose of the antihypertensive agent.
2) Be careful as excessive sedation may occur due to concurrent use with alcohol, tranquilizers, or sleeping pills.
3) Topiramate did not affect the pharmacokinetics of flunarizine. Systemic exposure to flunarizine increased by 16% when migraine patients were coadministered with 50 mg of topiramate every 12 hours, and when administered alone, it increased by 14%. Steady-state pharmacokinetics of topiramate were not affected by flunarizine.
4) Long-term administration of flunarizine did not affect the breakdown of phenytoin, carbamazepine, valproic acid, or phenobarbital. In general, blood levels of flunarizine were lower in patients with epilepsy compared to healthy subjects administered similar doses of this antiepileptic drug. The blood protein binding of carbamazepine, valproic acid, and phenytoin was not affected by co-administration of flunarizine.
6. Administration to pregnant and lactating women
1) Since deformities (skeletal abnormalities) have been reported in animal tests (mice), it should not be administered to pregnant women or women who may be pregnant.
2) Avoid administration during breastfeeding and discontinue breastfeeding if unavoidable circumstances arise.
7. Administration to children
Safety for children has not been established (there is no experience with use).
8. Administration to elderly people
Administer with caution as extrapyramidal symptoms and depressive symptoms are likely to occur.
9. Treatment in case of overdose
Overdosage may cause sedation, excitement, and tachycardia, so in such cases, take appropriate measures such as gastric lavage and use activated charcoal if necessary.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
36 months from date of manufacture
Of 1 capsule
- Active ingredient: : Flunarizine hydrochloride (KP)----5.9mg (5mg as flunarizine)
- Additives (tar coloring): Red No. 3
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, capsule, colloidal silicon dioxide, talc
2. Effectiveness
1. Severe, intractable migraine
2. Dizziness due to dysfunction of the vestibular system
3. Dosage and dosage
1. Severe, intractable migraine
Initial dose: Flunarizine, 10 mg once, is administered orally in the evening once a day for adults under 65 years of age (5 mg once a time for adults over 65 years of age). If depression, extrapyramidal symptoms, or other severe side effects occur, or if symptoms do not improve after two months of administration, discontinue administration.
Maintenance dose: If maintenance therapy is necessary, administer 10 mg of this drug once every 2 days (5 mg once for those over 65 years of age) or reduce the dosage by administering 10 mg once a day for 5 days a week (5 mg once for those over 65 years of age) (take a break for 2 days). In addition, as maintenance therapy to prevent migraine, even if migraine symptoms do not appear, administration should be discontinued 6 months after the first dose, and only if symptoms recur, the dose should be restarted from the initial dose.
2. Dizziness due to dysfunction of the vestibular system: The Dosage and Administration are the same as for migraine, but the initial dose should not last longer than the period necessary to control dizziness symptoms (generally 2 months). In addition, if there is no clear improvement in symptoms even after taking the drug for 1 month for chronic dizziness or 2 months for paroxysmal dizziness, stop taking the drug.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients who did not completely stop bleeding after intracranial hemorrhage
2) Patients with acute myocardial infarction
3) Parkinson's disease patients
4) Patients with depressive symptoms or a history of depression
5) Pregnant women or women who may be pregnant
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients:
1) Patients with liver impairment
2) Elderly people
3. Adverse reactions
1) Clinical trial data
① Placebo control group, double-blind trial - Adverse drug reactions reported at a frequency of more than 1%
The safety of this drug (5 to 10 mg/day) was evaluated in 500 subjects (247 in the treatment group and 253 in the placebo group) who participated in two placebo-controlled, double-blind parallel clinical trials (one for the treatment of migraine and one for the treatment of dizziness).
Adverse drug reactions reported in more than 1% of patients receiving this drug are shown in Table 1 below.
Table 1. Adverse drug reactions reported in more than 1% of patients treated with this drug in two placebo-controlled, double-blind parallel clinical trials
※ Please check the attached document for details.
② Active control test - Adverse drug reactions reported at a frequency of more than 1%
To determine the incidence of adverse drug reactions, two double-blind, active control trials were conducted. In these two trials, 476 subjects received 10 mg/day of this drug, one for migraine and the other for the treatment of dizziness or migraine.
Table 2 below lists adverse drug reactions reported in at least 1% of patients receiving this medicine in active-controlled studies that are not included in Table 1.
Table 2. Adverse drug reactions reported in more than 1% of patients treated with this drug in two double-blind active-controlled trials
※ Please check the attached document for details.
③ Placebo and active control trials - Adverse drug reactions reported with an incidence of less than 1%
Among the two clinical trial data above, Table 3 shows additional adverse drug reactions that occurred in less than 1% of patients administered this drug.
Table 3. Adverse drug reactions reported in less than 1% of patients treated with this drug in placebo and active control trials
※ Please check the attached document for details.
2) Post-marketing data
Table 4 shows the adverse drug reactions first discovered in post-marketing experience with this drug. In the table, the frequencies are indicated as follows.
Very common ≥ 1/10
Common: ≥1/100 and <1/10
Uncommon: ≥1/1,000 and <1/100
Rarely ≥ 1/10,000 and < 1/1,000
Very rare <1/10,000, with isolated reports
Table 4. Adverse drug reactions identified in post-marketing experience with this drug according to frequency estimated from voluntary reporting rates
※ Please check the attached document for details.
3) Mental nervous system: Depressive symptoms may occur, so pay close attention to the patient's condition and discontinue administration if such symptoms appear.
4) Extrapyramidal symptoms: Extrapyramidal symptoms such as convulsions, decreased motor function, mask-like face, forward flexion posture, lip dyskinesia, tremor, stiffness, and gait disturbance may occur. In such cases, discontinue administration. In severe cases, take appropriate measures, such as administering anti-Parkinson drugs.
5) Liver: Rarely, elevations of AST, ALT, ALP, and LDH may occur, so observe thoroughly and discontinue administration if abnormalities are recognized.
6) Hypersensitivity: In rare cases, a rash may occur, so pay close attention to the patient's condition and discontinue administration if such symptoms appear.
7) Digestive system: In rare cases, dry mouth, stomach discomfort, constipation, nausea, loss of appetite, and diarrhea may occur.
8) Others: Occasionally, drowsiness, fatigue, helplessness, malaise, headache, dizziness, staggering, insomnia, facial flushing, weight gain, edema, urinary retention, excessive milk secretion, etc. may occur (excessive milk secretion is more common in women taking oral contraceptives).
4. General precautions
1) While taking this medicine, you may experience decreased motor function, a mask-like face, extrapyramidal symptoms or depressive symptoms, mainly in the anteversion posture (there are also reports that it is more common in women).
Since these symptoms may appear for several months after discontinuation of administration, pay attention to the following.
① While administering this drug, carefully observe the patient's condition and pay attention to early detection of extrapyramidal symptoms and depression symptoms. If these symptoms are suspected or appear, the administration should be discontinued immediately.
② In cases where extrapyramidal symptoms appear, observe thoroughly as activities of daily living, such as going up and down stairs or putting on and taking off clothes, may worsen.
③ Efficacy should be assessed approximately 2 months after starting this drug, and administration thereafter is as follows.
․If the effect is recognized: Check the effect regularly (about 1 month) and decide whether to administer it.
․If the effect is not recognized: Stop.
․If the effect cannot be judged: Take a temporary break from the medication and decide whether to administer it after sufficiently observing the condition of the patient.
2) Because it may cause drowsiness and lethargy, patients taking this medicine should be careful not to operate dangerous machinery, such as driving a car.
5. Interaction
1) When coadministered with antihypertensive agents, it is advisable to adjust the dose of the antihypertensive agent.
2) Be careful as excessive sedation may occur due to concurrent use with alcohol, tranquilizers, or sleeping pills.
3) Topiramate did not affect the pharmacokinetics of flunarizine. Systemic exposure to flunarizine increased by 16% when migraine patients were coadministered with 50 mg of topiramate every 12 hours, and when administered alone, it increased by 14%. Steady-state pharmacokinetics of topiramate were not affected by flunarizine.
4) Long-term administration of flunarizine did not affect the breakdown of phenytoin, carbamazepine, valproic acid, or phenobarbital. In general, blood levels of flunarizine were lower in patients with epilepsy compared to healthy subjects administered similar doses of this antiepileptic drug. The blood protein binding of carbamazepine, valproic acid, and phenytoin was not affected by co-administration of flunarizine.
6. Administration to pregnant and lactating women
1) Since deformities (skeletal abnormalities) have been reported in animal tests (mice), it should not be administered to pregnant women or women who may be pregnant.
2) Avoid administration during breastfeeding and discontinue breastfeeding if unavoidable circumstances arise.
7. Administration to children
Safety for children has not been established (there is no experience with use).
8. Administration to elderly people
Administer with caution as extrapyramidal symptoms and depressive symptoms are likely to occur.
9. Treatment in case of overdose
Overdosage may cause sedation, excitement, and tachycardia, so in such cases, take appropriate measures such as gastric lavage and use activated charcoal if necessary.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 2items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 2 | Headache Cap. | Hedak Capsule (Precautions for use) | 2009.10.07 | HWPHedak capsule (precautions for use) change (2009.10.07).hwp |
| 1 | Headache Cap. | Hedak Capsule (Precautions for use) | 2008.12.10 | HWPHedak capsule (precautions for use) change (2008.12.10).hwp |